Publications by authors named "Emad Sadaka"
Objectives: The To distinguish between basal and non-basal subtypes of triple-negative breast cancers based on epidermal growth factor receptor and cytokeratin 5/6, and to establish the association of the diagnosis with clinicopathological parameters and survival rates.
Method: The retrospective study was conducted at the Clinical Oncology and Nuclear Medicine Department of Kafrelsheikh University Hospital and Tanta University Hospital, Egypt, and comprised medical records from January 2014 to December 2018 related to cases with histopathologically proven triple-negative breast cancer who had been treated and followed up for at least 5 years. The cases had been evaluated using immunohistochemistry for epidermal growth factor receptor and Cytokeratin 5/6 expression.
Article Synopsis
- - The study compares cardiac event rates in left breast cancer patients undergoing adjuvant radiotherapy using two techniques: breath-hold (DIBH) and free breathing (FB), involving a retrospective review of 432 patients.
- - Results showed that the doses received by the heart and the left anterior descending artery were significantly lower in the DIBH group compared to the FB group, leading to fewer cardiac events, although the difference was not statistically significant.
- - Key risk factors for cardiac events identified in the DIBH group included age, diabetes, hypertension, smoking, and radiation dose to the heart, with hypertension and smoking being independent risk factors.
Objective: Limited data is available to guide non-surgical management of Stage T4 larynx and hypopharynx cancer patients who have inoperable disease or refuse surgery. We aim to review the nonoperative management of T4 laryngeal and hypopharyngeal cancer and report the long-term therapeutic and functional outcomes.
Methods: We reviewed the nonoperative management of T4 laryngeal (n = 44) and hypopharyngeal (n = 53) cancer from 1997 to 2015 and performed a univariate analysis (UVA).
Background And Objectives: Since previous studies have indicated there are improvements in overall survival, the aim of this phase II clinical study was to evaluate docetaxel every three weeks plus prednisone as first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC).
Methods: Thirty-five metastatic HRPC patients were treated with docetaxel 70 mg/m2 every 3 weeks plus oral prednisolone 5 mg twice daily at the clinical oncology departments of Tanta, Mansoura and Menofia university hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate.